Glycosmedia

Diabetes News Service

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookies Policy
  • News
  • Archive
  • Categories & Tags
  • Journal Watch
  • Updates
  • Education
  • Reviews
  • About us ▼
    • About Glycosmedia
    • Editorial Team
    • Frequently asked questions
    • Comments
    • Press Releases
    • Disclaimer
  • Subscribe
  • Contact

Diabetic Autonomic Neuropathy

September 12th 2014

Whilst many patients are aware of the microvascular complications of diabetes – eyes, kidneys, peripheral nerves etc, the Cinderella complication, diabetic autononomic neuropathy (DAN) tends to affect significant numbers of patients who are either unaware of the problem or ascribe their symptoms to another condition. At the same time, as it is not regularly screened for as part of routine care, it is not until the patient has significant and often debilitating symptoms that it starts to receive attention. A sub type of the peripheral neuropathies, and depending on which methodology is used, its prevalence varies between 16-35% of patients. The ubiquitous nature of the autonomic nervous system renders virtually all organs susceptible to autonomic dysfunction but tend to fall into several groups with associated symptoms:

Cardiovascular: orthostatic hypotension, resting tachycardia, exercise intolerance.

Gastrointestinal: gastroparesis, constipation, diarrhoea, oesophageal dysmotility, erratic glucose control.

Genitourinary: neurogenic bladder, sexual dysfunction (male and female)

Metabolic: hypoglycaemic unawareness

Vasomotor: anhydrosis, gustatory sweating, dry skin.

The problem for the patient and clinician is that many of these symptoms can easily be overlooked especially given the differential diagnoses including medication side effects, hypovolaemia, multi-system atrophy to name a few. Diagnosis depends on the organ system involved: for gastrointestinal, endoscopy can exclude other conditions and the presence of food residue after a prolonged fast can indicate gastroparesis. Oesophageal & anorectal manometry are also helpful. When it comes to treatment, the corner stone is tight glycaemic control as well as aggressive cardiovascular risk management. However, for specific symptoms, diarrhoea, which may be exacerbated by bacterial overgrowth, can be treated with antibiotics. Treatment of diarrhoea with or without constipation should be treated with prokinetic agents (such as Erythromycin) rather than with constipating agents. Gustatory sweating which can be particularly debilitating and anti-social does respond to anti-cholinergics such as propantheline.

However, the most serious of these relates to the cardiovascular symptoms especially as its presence is associated with a mortality rate up to 5 times higher than unaffected patients – and this in a condition (diabetes) where mortality generally increased. Tests include heart rate response to deep breathing (i.e. beat to beat heart rate variation), heart rate response to standing and response to the Valasalva manoeuvre. Management includes the use of β blockers and ACE inhibitors as well as drugs such as Fludrocortisone to manage postural blood pressure changes (although care needs to be taken not to exacerbate resting blood pressure).

In summary, DAN is a multi-system complication of diabetes, early recognition of which can prevent significant morbidity for many patients with diabetes.

Dr Mark Freeman

Categories: Updates

Diabetes Updates Archive

calendar-iconDiabetes Updates Archive ››

Subscribe

subscribe-iconFREE weekly updates by email Please CLICK HERE

Gold Sponsors

Boehringer IngelheimNovo NordiskNapp DiabetesAstraZeneca

Silver Sponsors

About Ascensia Diabetes CareWelsh Endocrinology and Diabetes Society (WEDS)Abbott Diabetes Care

FUNDING NOTICE

The Glycosmedia website and newsletter has been made possible with funding support from our sponsors. None of our sponsors have control over the content of the website, newsletter, apps, Twitter feed or RSS newsfeed.

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Advertisers

CRC Press

The organisations advertising in this section do not have any input into, or editorial control over the content of this website.

Join us on Facebook

Join us on Facebook

Please share Glycosmedia:

Follow us on Twitter

My Tweets

mobileGlycosmedia is also available as an App:

For iPhone and iPad | For Android devices


Sponsorship and Advertising

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Copyright © 2022 Glycosmedia Partnership